Nasdaq
$1.32▲ 4.76%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $56.3MShares out 42.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 10.1Pre-market26.10.01 22:168-KKey event#●●●#●●●#●●●
Gain Therapeutics, Inc.Bullish
Gain Therapeutics announced that its Phase 1b open-label extension study of rexaceract for Parkinson's disease demonstrated stabilization of motor symptoms over 12 months of dosing. Based on these results, the company plans to submit a new Phase 2 study protocol to the FDA in the coming weeks and initiate the trial in the first quarter of 2027.…more
$1.32+4.76%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.28After-hours26.09.29 05:308-KKey event
Gain Therapeutics, Inc.
Gianluca Fuggetta, the company's Principal Financial Officer and Principal Accounting Officer, will resign effective September 30, 2026. Gene Mack, the current President and CEO, has been appointed as interim CFO starting October 1, 2026, while the company continues its search for a permanent replacement.…more
$1.32+4.76%vs prev closeView filingShare - 8.11After-hours26.08.12 05:0710-QEarnings
Gain Therapeutics, Inc.
Gain Therapeutics(GANX)의 2026년 2분기(6월 30일 기준) 10-Q 분기 보고서가 제출되었습니다. 2026년 7월 31일 기준 회사의 발행 주식 수는 총 43,643,619주입니다.…more
$1.32+4.76%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Pre-market26.10.01 22:20#●●●#●●●#●●●
Gain Therapeutics Plans To Initiate Phase 2 Rexaceract Trial In Q1 Next Year…more
Gain Therapeutics announced its plan to initiate a Phase 2 clinical trial for Rexaceract in the first quarter of next year. While advancing to Phase 2 is a key milestone, the company remains in the early stages of drug development with no immediate revenue impact.…more
$1.32+4.76%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29After-hours26.09.30 06:50
●●●●●●●● ●●●●● ●●●●●●
Gain Therapeutics announced it will present long-term clinical data for its Parkinson’s disease drug candidate at the upcoming International Congress of Parkinson’s Disease and Movement Disorders. This presentation serves as an academic update and does not represent a material financial event for the company.…more
$1.32+4.76%vs prev close - 9.28After-hours26.09.29 05:37
●●●●●●●● ●●●●● ●●●●●●
Gain Therapeutics has appointed CEO Gene Mack as interim CFO, effective October 1. He will succeed the outgoing Principal Financial Officer, Gianluca Fuggetta.…more
$1.32+4.76%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report